Table 1.

Predictors of eGFR slope over a median 4.5 years of follow-up: univariable and multivariable analysis

	Univariable analysis					Multivariable analysis
	β coef.	SE	P-value	LCL	UCL	β coef.	SE	P-value	LCL	UCL
Urine markers
Log UPodCR	−2.58	0.56	<0.001	−3.7	−1.46	−2.17	0.62	0.001	−3.41	−0.93
Log UNephCR	−1.83	0.64	0.005	−3.09	−0.56
Log UAqp2CR	0.09	0.53	0.86	−0.96	1.15
Log UTGFβ1CR	−0.82	0.32	0.01	−1.46	−0.18	−0.14	0.35	0.69	−0.83	0.55
Log UProtCR	−1.44	0.56	0.01	−2.55	−0.34	0.15	0.59	0.81	−1.03	1.33
Recipient
Age	−0.02	0.04	0.69	−0.10	0.07
Black race	−4.80	1.61	0.004	−7.98	−1.60	−1.91	1.48	0.20	−4.85	1.00
Gender, male	3.02	1.23	0.02	0.59	5.47	1.41	1.21	0.25	−0.98	3.80
BSA	2.15	2.33	0.36	−2.48	6.77
cPRA	−0.05	0.02	0.02	−0.10	−0.01	−0.02	0.02	0.26	−0.06	0.02
Previous transplant	−1.47	2.72	0.59	−6.87	3.92
Dialysis vintage (ref: 0–2 years)
Preemptive	2.23	1.56	0.16	−0.86	5.33
Dialysis >2 years	0.71	1.44	0.62	−2.15	3.57
Cause of renal disease (ref: PKD)
Congenital/familial	1.22	3.15	0.70	−5.01	7.46
Glomerular	−0.35	2.36	0.88	−5.04	4.33
Hypertension	1.40	2.57	0.59	−3.70	6.51
Diabetes	−2.67	2.30	0.25	−7.22	1.88
Other	−3.16	2.54	0.22	−8.21	1.88
Donor
Age	−0.00	0.05	0.94	−0.10	0.09
AA (ref: non-AA)	−2.81	1.97	0.16	−6.71	1.09
Male sex	−1.62	1.26	0.20	−4.12	0.89
BSA	1.71	2.29	0.46	−2.83	6.25
Transplant
Cadaveric transplant	−1.92	1.31	0.15	−4.52	0.68
Cold ischemia time	−0.18	0.08	0.03	−0.33	−0.02	−0.10	0.07	0.16	−0.25	0.04
HLA mismatch
3–4	0.88	1.59	0.58	−2.27	4.02
5–6	0.64	1.63	0.70	−2.60	3.87
First-year events
DSA in first year	−1.50	1.57	0.34	−4.62	1.62
Rejection in first year	−0.19	1.22	0.88	−6.37	5.43
First-year biopsies
GGS >10% (ref: GGS <10%)	−5.67	1.78	0.002	−9.19	−2.15	−4.20	1.65	0.01	−7.50	−0.94
GD (TG or recurrent disease)	−8.66	2.22	<0.001	−13.1	−4.26	−5.77	2.04	0.006	−9.83	−1.70
IFTA (ref: No IFTA)
Mild	0.77	1.33	0.57	−1.87	3.40	0.63	1.15	0.59	−1.65	2.90
Moderate–severe	−3.88	1.84	0.04	−7.54	−0.23	−1.24	1.76	0.48	−4.72	2.25

Coefficient values of urine markers represent the coefficients of their log-transformed values. The slope of eGFR can be obtained by multiplying the β-coefficient with the log of the fold increase desired. For example, a 3-fold increase in UPodCR would be β × log₂(3) = −2.17 × 1.58 = −3.4 mL/min/1.73 m²/year. The β-coefficient for other values represents the change in eGFR in mL/min/1.73 m²/year. Urine nephrin was excluded from multivariable analysis due to collinearity with podocin mRNA. IFTA was defined as mild (<25%), moderate (25–50%) and severe as (>50% of the total area).

Coef., coefficient; SE, standard error; UPodCR, urine podocin mRNA:urine creatinine ratio; UNephCR, urine nephrin mRNA:creatinine ratio, UAqp2CR, urine aquaporin2 mRNA:urine creatinine ratio; UTGFβ1CR, urine transforming growth factor β mRNA:urine creatinine ratio; UProtCR, urine protein:urine creatinine ratio; AA, African American; cPRA, calculated panel reactive antibody; PKD, polycystic kidney disease, HLA, human leukocyte antigen; TG, transplant glomerulopathy; LCL, lower confidence limit; UCL, upper confidence limit.